--- title: "ProMIS Neurosciences: Strengthened Balance Sheet and Differentiated PMN310 Alzheimer’s Program Underpin Buy Rating" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/280676544.md" description: "In a recent report, Jason McCarthy from Maxim Group maintained a Buy rating on ProMIS Neurosciences with a price target of $35.00. He cites the company's strengthened balance sheet and the fully enrolled Phase 1b PRECISE-AD trial for PMN310 in early Alzheimer’s disease as key factors. The recent $175M PIPE extends the cash runway through 2027, supporting both IV and subcutaneous formulations. McCarthy highlights PMN310’s unique mechanism and safety profile, which may differentiate it from existing therapies like Leqembi." datetime: "2026-03-26T18:05:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280676544.md) - [en](https://longbridge.com/en/news/280676544.md) - [zh-HK](https://longbridge.com/zh-HK/news/280676544.md) --- > 支持的语言: [English](https://longbridge.com/en/news/280676544.md) | [繁體中文](https://longbridge.com/zh-HK/news/280676544.md) # ProMIS Neurosciences: Strengthened Balance Sheet and Differentiated PMN310 Alzheimer’s Program Underpin Buy Rating In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on ProMIS Neurosciences, with a price target of $35.00. ### Claim 30% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Jason McCarthy has given his Buy rating due to a combination of factors tied to ProMIS Neurosciences’ lead asset and strengthened balance sheet. He highlights that PMN310’s Phase 1b PRECISE-AD trial in early Alzheimer’s disease is fully enrolled, with a blinded six‑month interim analysis in 3Q26 and 12‑month topline data in early 2027 expected to provide key efficacy and safety signals. He also points to the recent $175M PIPE, including $75.5M already raised, which extends the cash runway through 2027 and funds both the IV and planned subcutaneous formulations of PMN310. McCarthy emphasizes that PMN310’s oligomer‑focused mechanism and clean safety profile to date, including no ARIA observed so far, could differentiate it versus existing therapies like Leqembi and support a potential single registrational study if data and FDA feedback are favorable. According to TipRanks, McCarthy is an analyst with an average return of \-15.8% and a 28.26% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Moleculin Biotech, Gain Therapeutics, and SELLAS Life Sciences Group. ### 相关股票 - [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md) - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md) - [Minerva Neurosciences (NERV.US)](https://longbridge.com/zh-CN/quote/NERV.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [ProMIS Neurosciences (PMN.US)](https://longbridge.com/zh-CN/quote/PMN.US.md) - [Biogen (BIIB.US)](https://longbridge.com/zh-CN/quote/BIIB.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [Alto Neuroscience (ANRO.US)](https://longbridge.com/zh-CN/quote/ANRO.US.md) - [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-CN/quote/LABU.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) ## 相关资讯与研究 - [](https://longbridge.com/zh-CN/news/281382916.md) - [FDA approves new high dose Spinraza regimen for SMA](https://longbridge.com/zh-CN/news/281376767.md) - [09:25 ETFDA Approves High Dose Regimen of SPINRAZA for People Living with SMA](https://longbridge.com/zh-CN/news/281029677.md) - [Biogen, with $5.6B Apellis buy, builds out immunology offerings](https://longbridge.com/zh-CN/news/281425584.md) - [BUZZ-Street View: Biogen's $5.6 billion Apellis bet a strategic fit](https://longbridge.com/zh-CN/news/281357962.md)